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tivariate sensitivity analysis (MSA) was carried out to assess the
robustness of results. RESULTS: RLAI generates health beneﬁts
of 0.04 QALYs over olanzapine (mainly due to improved com-
pliance) and 0.15 QALYs over haloperidol depot (mainly due to
improved symptom control). Cost-savings are generated over
both comparators (Sweden: €425 [4000 kr] and €5750
[~54,000 kr]) as reductions in hospitalization and psychiatrist
costs offset medication costs. Health gains combined with cost
savings imply dominance. The MSA suggest results are robust
to changes in parameters, but respond to patient distribution
and the modeled treatment differences (in terms of side effects,
compliance, and symptom reduction). The MSA showed that
there is a 57% and 93% chance that RLAI dominates olanza-
pine and haloperidol depot respectively. Health gains and cost
savings due to RLAI are largest amongst the more severe
patients. Average time until treatment discontinuation on halo-
peridol depot, olanzapine and RLAI is predicted to be 1.11,
1.24 and 1.44 years, respectively. CONCLUSION: RLAI is
predicted to dominate olanzapine and haloperidol depot in
Sweden. Outcomes are robust to reasonable changes in input
parameters. Health beneﬁts and cost savings are largest amongst
more severe patients.
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OBJECTIVES: Compliance amongst schizophrenia patients is
typically poor. Consequently treatments which are equally efﬁ-
cacious under trial-based conditions but face different compli-
ance rates in clinical practice (e.g. due to side-effect proﬁle, ease
of use, reputation) may result in differences in effectiveness not
observed during trials. This study analyzes the impact of differ-
ences in compliance on antipsychotics using a pharmacoeco-
nomic discrete event simulation (DES) model, adapted to the
Swedish treatment setting. METHODS: An existing ﬁve-year
DES model was adapted such that the treatment arms under
comparison were identical, except in terms of the share of com-
pliant patients. Non-compliant patients experience shorter times
between relapses and have inferior symptom control compared
to their compliant counterparts. The difference in compliance
was varied from 0 to 15%, and incremental costs and effects
were recorded and analyzed. RESULTS: With a 5%, 10% and
15% difference in compliance, incremental effects increase to
0.021, 0.037 and 0.058 respectively, while cost-savings are gen-
erated of 31,000 kr, 55,000 kr and 83,000 kr respectively
(9.3 kr = 1€). Hence, each %-point of compliance gain is pre-
dicted to roughly result in cost-savings of 6,000 kr and QALY
gains of 0.004. On average, the model predicts that with a 10%
increase in compliance 0.4 relapses are prevented, average
PANSS decreases by 3 points and patients spend 23 days less in
hospital over 5 years. CONCLUSION: The DES model predicts
that increases in compliance may lead to considerable cost-
savings and health improvements. Hence efﬁcacy rates from clini-
cal trials should not be interpreted at face value, but should be
discussed in tandem with expectations concerning compliance, in
light of product characteristics such as side-effects. These results
further suggest that efforts to improve compliance among schizo-
phrenics (including non-pharmacological efforts, such as family
therapy, phone message reminders, etc) are expected to prove
cost-effective if their compliance gains outweigh their additional
costs.
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OBJECTIVES: To assess the cost-effectiveness of olanzapine
versus generic risperidone and other antipsychotics in standard
oral formulations—quetiapine, ziprasidone, aripiprazole, and
perphenazine—in the usual treatment of schizophrenia patients
from a U.S. health care system perspective. METHODS: Pub-
lished medical literature, unpublished data and clinical expert
panel were used to populate a micro-simulation model compar-
ing six antipsychotics in the usual care of schizophrenia. The
1-year model captures clinical and cost parameters including
adherence levels, treatment discontinuation rates by reason,
relapse with and without inpatient hospitalization, quality
adjusted life years, treatment-emergent adverse events, health
care resource utilization and associated costs. Sequential bifur-
cation identiﬁed the most important input parameters on which
sensitivity analyses were performed. Key results included mean
2007 annual direct cost per treatment and incremental cost-
effectiveness values among treatments for cost per stable relapse-
free quarter, cost per inpatient relapse avoided, and cost per
QALY gained. RESULTS: Based on model projections, the
annual proportion of stable relapse-free patients was 71% for
olanzapine, 56% for risperidone. The proportion of patients
experiencing inpatient relapse was 26% for olanzapine, 40% for
risperidone. QALY were 0.747 for olanzapine and 0.723 for
risperidone. Total health care cost was $9,471 for olanzapine and
$11,093 for generic risperidone, driven by higher inpatient hos-
pitalization for risperidone therapy. Sensitivity analyses found
olanzapine to be the dominant choice at any cost of generic
risperidone, even when given free. All other comparators in the
model were also dominated by olanzapine. The model was found
by an independent cost-effectiveness expert to fulﬁll ISPOR task
force’s 13 recommended attributes of a good decision model.
CONCLUSION: The utilization of olanzapine is predicted in
this model to result in better clinical outcomes and lower total
health care costs compared to generic risperidone, quetiapine,
ziprasidone, aripiprazole, and perphenazine. Olanzapine may
therefore be a cost-effective therapeutic option for patients with
schizophrenia.
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OBJECTIVES: Paliperidone Extended-Release OROS (ER) is a
new atypical antipsychotic for schizophrenia. The cost effective-
ness of paliperidone ER compared to olanzapine was analyzed
in a Swedish, Norwegian, Finnish and Danish setting, using a
pharmacoeconomic discrete event simulation (DES) model.
METHODS: Following interviews with local expert panels an
existing DES model, which simulates individual schizophrenia
patients over a ﬁve-year time period, was adapted to reﬂect
schizophrenia treatment and comply with local health-economic
guidelines in Sweden, Finland, Denmark and Norway. Model
inputs were derived from clinical trial data, literature and data-
base analysis and expert opinion. Cost estimates depend on
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treatment and treatment location; quality of life depends on
symptom severity (measured by the PANSS score) and side-
effects. Multivariate sensitivity analyses were carried out to
assess the robustness of results. RESULTS: An indirect compari-
son of trial data suggests that paliperidone ER (6 mg) and olan-
zapine (10 mg) are equally efﬁcacious in terms of PANSS
reduction, while the former has a superior side-effect proﬁle,
especially with respect to weight gain and sedation. In the model
this reduction in side effects on paliperidone ER translates into
(discounted) QALY gains of ~0.03 compared to olanzapine.
These health beneﬁts are realized at (discounted) incremental
costs ranging from -€3200 (-23,800 DKK) in Denmark to cost-
neutrality in Finland, suggesting either dominance or cost-
effectiveness in all four countries. The sensitivity analysis
suggests results are robust to changes in input parameters. If the
side-effect proﬁle of paliperidone ER is assumed to improve
compliance, further cost-savings and QALY gains are predicted.
CONCLUSION: Based on the available evidence and input from
local experts, paliperidone ER is predicted to dominate olanza-
pine in Sweden, Norway, Finland and Denmark. Results are
robust to changes in input parameters. Improved compliance on
paliperidone ER due to reduced side effects would further
strengthen its predicted dominance.
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OBJECTIVES: To estimate cost-effectiveness of various therapy
scenarios of treating schizophrenia with amisulprid (Solian), a
medicine of 2nd generation, in comparison with haloperidol.
METHODS: Cost-effectiveness decision model was prepared.
Treatment with amisulprid vs haloperidol was compared in fol-
lowing scenarios: Ø Scenario 1—amisulprid vs haloperidol
(with change for risperidon in case of recurrence in any arm) Ø
Scenario 2—amisulprid vs. haloperidol for 1 year (as ﬁrst line
medicine) followed by treatment with new atypical medicine
(olanzapina or risperidon) in case of recurrence. The target
population was patients suffered from chronic schizophrenia, at
the moment of exacerbation of disease. Analysis was performed
from the payers’ perspective (the National Health Budget and
patient), with a time horizon of 1 year. Estimates of effective-
ness were expressed with QALY (quality adjusted life years).
Following parameters were considered: risk of extrapyramidal
symptoms, recurrence, suicide and rates of compliance. Costs
of medicines (ﬁrst line therapy with amisulprid or haloperidol
and possibly second line therapy with olanzapina or risperidon
in case of recurrence in haloperidol arm), correcting therapy
with olanzapine or rispridone in case of recurrenece), treatment
of EPS, hospitalisation due to reccurence and outpatient con-
sultations were taken into account. RESULTS: In the scenario 1
cost of 1 QALY due to replacing standard ﬁrst line therapy
with haloperidol by amisulprid is 1601 PLN. In scenario 2,
using amisulprid during one year instead of haloperidol as ﬁrst
line therapy followed by olanzapina in case of recurrance,
brings additional costs of 275 PLN and gives additional QALY
0.056 year. Cost of quality adjusted life year is 4935 PLN.
CONCLUSION: Treatment of schizophrenia with amisulprid
during whole year, instead of haloperidol as ﬁrst line therapy
followed by risperidon in case of recurrence, is a cost effective
therapy.
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OBJECTIVES: This study determines the cost-effectiveness of 3
antipsychotics for the treatment of schizophrenia in Belgium.
METHODS: Data were retrieved from a prospective observa-
tional non randomized follow-up survey. Clinical investigators
included 293 schizophrenic patients; 136 of those patients were
assigned to Olanzapine, 129 to Risperidone and 28 to Haloperi-
dol. Patients were followed for 2 years. Total health care costs
were determined from the perspective of the public payer and
calculated by multiplying resource use with ofﬁcial tariffs; effec-
tiveness of the drugs was measured with EQ-5D. Several studies
have already compared the cost-effectiveness of different antip-
sychiotics for the treatment of schizophrenia, most of them are
however ﬂawed by methodological issues. This study therefore
uses a new method that was developed to address these limita-
tions but is not widely used yet: the net-beneﬁt regression
approach (NBRA). We show its merits by performing a cost-
effectiveness analysis of Olanzapine, Risperidone and Haloperi-
dol. RESULTS: Models were checked for selection bias but drug
choice was not endogenous; we therefore proceeded with simple
OLS regressions. The results indicate that the drugs provide
similar net monetary beneﬁts to the patient (H vs. O -4452.53
(p = 0.645), R vs. O 4439.54 (p = 0.425), R vs. H 8892.07
(p = 0.366)). When we control for several patient characteristics
R moves away further from H and O but the difference does not
reach statistical signiﬁcance (R vs. O 5857.73 (p = 0.332), R vs.
H 15233.53 (p = 0.178)). Several important patient subgroups
were also identiﬁed; they indicate that a drug performs better in
a speciﬁc patient group. Numerous sensitivity analyses conﬁrm
the robustness of the results. CONCLUSION: We conclude by
conﬁrming that the NBRA is an important enrichment to the
CEA methodology. As was demonstrated in this paper, it is often
important to correct cost-effectiveness results for patient charac-
teristics and to identify signiﬁcant patient subgroups.
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OBJECTIVES: Major depressive disorder (MDD) remains highly
under-treated and accounts for substantial health system costs.
Duloxetine, a new serotonin and norepinephrine reuptake inhibi-
tor, has been shown to be effective and safe in treatment of
depression. This study examined the cost-effectiveness of dulox-
etine vs. Selective Serotonin Reuptake Inhibitors (SSRIs: ﬂuoxet-
ine, paroxetine, sertraline, citralopram and escitalopram) and
venlafaxine extended-release (XR) from the Spanish health
system perspective. METHODS: A Markov decision model
simulated clinical management of MDD patients during six
2-month cycles in primary or secondary care. Patients on acute
treatment could experience remission, response without remis-
sion, no response, or discontinuation of initial therapy. Non–
responders and partial responders could continue therapy or
switch to another therapy. Efﬁcacy data and utility data were
derived from clinical trials. Treatment patterns were obtained
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